Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCB301 in Advanced Solid Tumors or Relapsed and Refractory cHL
NCT06487624Phase 1Recruiting
- Sponsor
- FBD Biologics Limited
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Antibody Fragments, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of HCB301 in solid tumor (advanced stage) and classical Hodgkin lymphoma (cHL) (7 arms), sponsored by FBD Biologics Limited. Primary endpoints: Incidence and percentage of subjects with adverse events at 12 months, Anti-Drug Antibodies at 12 months and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
HCB301
03
Conditions
solid tumor (advanced stage)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06487624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487624.